Amphastar Pharmaceuticals

Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer

Retrieved on: 
Wednesday, April 10, 2024
Mallinckrodt, Financial management, University, Information, Treasury, Sharecare, United Therapeutics, Virginia School for Girls, Hereditary angioedema, Acquisition, Accounting, HAE, Therapy, Amphastar Pharmaceuticals, Strategic planning, Management

In this role, he will be responsible for refining and implementing Pharvaris’ corporate financial strategy and activities including financial reporting and operations.

Key Points: 
  • In this role, he will be responsible for refining and implementing Pharvaris’ corporate financial strategy and activities including financial reporting and operations.
  • “David expands Pharvaris’ leadership capabilities as we become a late-stage biotech company with an exciting pipeline and strong commercial potential,” said Berndt Modig, Chief Executive Officer of Pharvaris.
  • He will work closely on investor relations and corporate strategy with Morgan Conn, our Chief Business Officer.
  • Over his career, Mr. Nassif has served as the Chief Financial Officer of Histogen, Zogenix, Amphastar Pharmaceuticals, and RealAge.

Lilly to Divest BAQSIMI to Amphastar

Retrieved on: 
Monday, April 24, 2023
CIBC Bank USA, AMPH, P.C, Insulin, JPMorgan Chase, Covington & Burling, Gland, Diabetes, Kirkland & Ellis, Marketing, Neoplasm, Cathay Bank, Glucagon, Pancreas, Wilson Sonsini Goodrich & Rosati, GAAP, Obesity, Wilson, Capital One, Eli Lilly, Wells Fargo, LLY, Jefferies Group, Hypoglycemia, Acquisition, Allergy, Patient, Insulinoma, Pheochromocytoma, J. P. Morgan, Growth, NYSE, Fifth Third Bank, Eli Lilly and Company, Pharmaceutical industry, Bank, Amphastar Pharmaceuticals, Lilly

INDIANAPOLIS and RANCHO CUCAMONGA, Calif., April 24, 2023 /PRNewswire/ -- In an effort to continue expanding the availability of BAQSIMI® to patients, Eli Lilly and Company (NYSE: LLY) and Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) have entered into a definitive agreement for Lilly to divest BAQSIMI worldwide to Amphastar, a global pharmaceutical company focused on developing, manufacturing, and marketing injectable, intranasal, and inhalation products including experience with a glucagon product. BAQSIMI is the first and only nasally administered glucagon for the treatment of severe hypoglycemia in people with diabetes.

Key Points: 
  • INDIANAPOLIS and RANCHO CUCAMONGA, Calif., April 24, 2023 /PRNewswire/ -- In an effort to continue expanding the availability of BAQSIMI® to patients, Eli Lilly and Company (NYSE: LLY) and Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) have entered into a definitive agreement for Lilly to divest BAQSIMI worldwide to Amphastar, a global pharmaceutical company focused on developing, manufacturing, and marketing injectable, intranasal, and inhalation products including experience with a glucagon product.
  • Amphastar expects to provide dedicated commercial investment for BAQSIMI with the goal of enabling more people on insulin to be prepared with a glucagon rescue treatment for severe hypoglycemia.
  • Lilly launched BAQSIMI in 2019 as an option to quickly render aid in rescue situations for people with diabetes who take insulin and it is currently available in 27 international markets.
  • Each of Lilly and Amphastar will determine their applicable accounting treatment for this transaction according to Generally Accepted Accounting Principles (GAAP) upon closing.

Global Respiratory Disposables Market Report 2022: Market is Expected to Grow to $4.24 Billion in 2026 - Long-term Forecast to 2031 - ResearchAndMarkets.com

Retrieved on: 
Monday, July 18, 2022
Medical Supplies, Health, Adult, Acquisition, OSA, Disease, Hospital, Mask, Asthma, Smoking, MEDLINE, Mojo, Skin, Technology, Respiratory disease, Respiratory system, Salbutamol, Air pollution, Amphastar Pharmaceuticals, Respironics, Marketing, CFC, Electricity, Fisher & Paykel, Chronic obstructive pulmonary disease, Degenerative disease, Animal glue, Aerogel, National Institute for Occupational Safety and Health, Prevalence, Lung cancer, Obstructive sleep apnea, Health, COPD, Epinephrine (medication), ResMed, AIR, BESM-6, FDA, Tuberculosis, Hudson, OSHA, Poultry, Personal protective equipment, Fossil fuel, Pharmaceutical industry, Teleflex

The "Global Respiratory Disposables Market Report 2022" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Respiratory Disposables Market Report 2022" report has been added to ResearchAndMarkets.com's offering.
  • The respiratory disposables market consists of sales of respiratory disposables and related services.
  • The high prevalence rate of respiratory diseases globally is driving the respiratory disposables market.
  • Global Respiratory Disposables Forecast Market, 2021-2026F, 2031F, $ Billion

MannKind Corporation Reports 2021 Fourth Quarter and Full Year Financial Results

Retrieved on: 
Thursday, February 24, 2022
GLOBE, United Therapeutics, MannKind Corporation, Treprostinil, Investment, Research, Total revenue, COVID-19, PPP, Sale, Clofazimine, Doctor of Pharmacy, UT, License, Net, Acquisition, Call, Mission statement, GAAP, Cryptocurrency, Pharmaceutical industry, Financial services, Bank, Animal, Amphastar Pharmaceuticals, Conference, Inhalable insulin

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) today reported financial results for the fourth quarter and full year ended December 31, 2021.

Key Points: 
  • Afrezza gross margin in the fourth quarter of 2021 was 62% compared to 64% for the same period in 2020.
  • Research and development (R&D) expenses for the fourth quarter of 2021 were $3.9 million compared to $1.5 million for the fourth quarter of 2020.
  • Selling, general and administrative (SG&A) expenses for the fourth quarter of 2021 were $22.7 million compared to $17.1 million for the fourth quarter of 2020.
  • The net loss for the fourth quarter of 2021 was $28.1 million, or $0.11 per share, compared to $26.4 million in the fourth quarter of 2020, or $0.11 per share.

Sio Gene Therapies Announces Prioritization of Lead Gene Therapy Programs in GM1 and GM2 Gangliosidosis, Extension of Cash Runway, and CEO Transition

Retrieved on: 
Monday, January 31, 2022
CNS, GM1, CSF, CEO, Patient, Private Securities Litigation Reform Act, Therapy, NASDAQ, Organization, University, Lists of diseases, COVID-19, Type, CFO, General counsel, United Therapeutics, Sandhoff disease, Board, Serum, GM2, Program, NEW, Executive, U.S. Securities and Exchange Commission, Biomarker, Information, Company, BS, Neurodegeneration, Financial management, Child development stages, GLOBE, Tay–Sachs disease, Business, Mallinckrodt, Acquisition, Imagination, SIOX, Industry, Amphastar Pharmaceuticals, Security (finance), Director, Regenerative medicine, AAV, Virginia School for Girls, Pharmaceutical industry, Management

NEW YORK and DURHAM, N.C., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases, today provided a corporate update announcing the prioritization of AXO-AAV-GM1 and AXO-AAV-GM2, its clinical stage AAV gene therapy programs for GM1 and GM2 gangliosidosis (Tay-Sachs/Sandhoff disease). The portfolio prioritization extends the Company’s estimated cash runway into the second half of 2023, beyond multiple key clinical milestones for both gene therapy programs. With this prioritization, the company intends to terminate its licensing agreement with Oxford Biomedica for AXO-Lenti-PD, its lentiviral gene therapy program for Parkinson’s disease.

Key Points: 
  • The portfolio prioritization extends the Companys estimated cash runway into the second half of 2023, beyond multiple key clinical milestones for both gene therapy programs.
  • With this prioritization, the company intends to terminate its licensing agreement with Oxford Biomedica for AXO-Lenti-PD, its lentiviral gene therapy program for Parkinsons disease.
  • I believe our programs in GM1 and GM2 have the ability to transform the care for patients and deserve this heightened focus.
  • Dr. Cheruvu added, Serving as the CEO of Sio for the last four years has been an immense privilege.

MannKind Corporation Reports 2021 Third Quarter Financial Results

Retrieved on: 
Tuesday, November 9, 2021
Mission statement, Call, United Therapeutics, Total revenue, SG, Investment, MannKind Corporation, COVID-19, Research, Clofazimine, Table, Levothyroxine, UT, GLOBE, Small business, GAAP, PPP, Forgiveness, Amphastar Pharmaceuticals, Doctor of Pharmacy, Midcap, Total, Professional corporation, Cryptocurrency, Pharmaceutical industry, Financial services, Security (finance), Bank

WESTLAKE VILLAGE, Calif., Nov. 09, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) today reported financial results for the quarter and nine months ended September 30, 2021.

Key Points: 
  • Research and development (R&D) expenses for the third quarter of 2021 were $3.7 million compared to $1.5 million for the third quarter of 2020.
  • Selling, general and administrative (SG&A) expenses for the third quarter of 2021 were $17.2 million compared to $13.9 million for the third quarter of 2020, an increase of $3.3 million, or 24%.
  • Interest expense on debt for the third quarter of 2021 was $2.8 million compared to $2.4 million for the third quarter of 2020.
  • We believe that these non-GAAP financial measures, when considered together with our GAAP financial results, provide management and investors with an additional understanding of our business operating results, including underlying trends.

Amphastar Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference

Retrieved on: 
Thursday, May 27, 2021
Amphastar Pharmaceuticals

RANCHO CUCAMONGA, Calif., May 27, 2021 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters, Executive V.P.

Key Points: 
  • RANCHO CUCAMONGA, Calif., May 27, 2021 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters, Executive V.P.
  • Corporate Administration Center and Sales & Marketing, will participate in an Analyst-Moderated fireside chat at the Jefferies Virtual Healthcare Conference on Thursday, June 3, 2021 at 2:30 pm Eastern time.
  • This presentation will be made available webcast and may be accessed by visiting Amphastars Pharmaceuticals website at http://ir.amphastar.com .
  • The Amphastar Pharmaceuticals logo and other trademarks or service marks of Amphastar Pharmaceuticals,Inc., including, but not limited to Primatene MIST, Amphadase and Cortrosyn, are the property of Amphastar Pharmaceuticals,Inc.

Amphastar Pharmaceuticals to Present at the 20th Annual Needham Virtual Healthcare Conference

Retrieved on: 
Tuesday, April 6, 2021
Amphastar Pharmaceuticals, Pharmaceutical industry in China, Health care, Health, Pharmacy

Corporate Administration Center and Sales & Marketing, will participate in an Analyst-Moderated fireside chat at the Needham Virtual Healthcare Conference on Tuesday, April 13, 2021 at 3:45 pm Eastern time.

Key Points: 
  • Corporate Administration Center and Sales & Marketing, will participate in an Analyst-Moderated fireside chat at the Needham Virtual Healthcare Conference on Tuesday, April 13, 2021 at 3:45 pm Eastern time.
  • This presentation will be made available webcast and may be accessed by visiting Amphastars Pharmaceuticals website at http://ir.amphastar.com .
  • Amphastar is a specialty pharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and intranasal products.
  • The Amphastar Pharmaceuticals logo and other trademarks or service marks of Amphastar Pharmaceuticals,Inc., including, but not limited to Primatene, Amphadase and Cortrosyn, are the property of Amphastar Pharmaceuticals,Inc.

Amphastar Pharmaceuticals Receives FDA Approval for Dextrose Injection

Retrieved on: 
Monday, March 29, 2021
Medical equipment, Amphastar Pharmaceuticals, Drug paraphernalia, Syringe, Injection, Science and technology, Technology, Health sciences

RANCHO CUCAMONGA, Calif., March 29, 2021 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the U.S. Food and Drug Administration (FDA) approved the Companys Abbreviated New Drug Application (ANDA) for Dextrose injection 50% in the 50 mL Luer-Jet Prefilled Syringe System.

Key Points: 
  • RANCHO CUCAMONGA, Calif., March 29, 2021 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the U.S. Food and Drug Administration (FDA) approved the Companys Abbreviated New Drug Application (ANDA) for Dextrose injection 50% in the 50 mL Luer-Jet Prefilled Syringe System.
  • Net revenues for the Companys Dextrose injection for the year ended December 31, 2020, were $7.6 million.
  • Amphastar is a bio-pharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and intranasal products.
  • Amphastars logo and other trademarks or service marks of Amphastar, including, but not limited to Amphastar, Primatene Mist, Amphadase, and Cortrosyn, are the property of Amphastar.

Amphastar Pharmaceuticals to Present at the Raymond James 2021 Institutional Healthcare Conference

Retrieved on: 
Friday, February 26, 2021
Amphastar Pharmaceuticals, Pharmaceutical industry in China, Health care, Pharmacy, Health

Corporate Administration Center and Sales & Marketing, will participate in an Analyst-Moderated fireside chat at the Raymond James 2021 Institutional Healthcare Conference on Tuesday, March 2, 2021 at 1:20 pm Eastern time.

Key Points: 
  • Corporate Administration Center and Sales & Marketing, will participate in an Analyst-Moderated fireside chat at the Raymond James 2021 Institutional Healthcare Conference on Tuesday, March 2, 2021 at 1:20 pm Eastern time.
  • This presentation will be made available webcast and may be accessed by visiting Amphastar Pharmaceuticals' website at http://ir.amphastar.com .
  • Amphastar is a specialty pharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and intranasal products.
  • The Amphastar Pharmaceuticals logo and other trademarks or service marks of Amphastar Pharmaceuticals,Inc., including, but not limited to Primatene, Amphadase and Cortrosyn, are the property of Amphastar Pharmaceuticals,Inc.